Blood transfusion

NHS to roll out new genetic blood matching test to curb side effects of blood transfusions

Thousands of patients across England are set to benefit as the NHS gears up to launch a new programme that will circumvent the adverse side effects related to blood transfusions for sickle cell disease or thalassaemia.

As part of this “landmark” new initiative, the health service would undergo a detailed analyses of patients’ blood groups to ensure those needing blood are matched with the best possible donors, thus reducing side effects and improving outcomes.

This would make the NHS the first health system globally to deliver blood group genotyping.

Approximately 17,000 people live with sickle cell disease in England with the disease being especially common in those of Black African and Caribbean heritage. Thalassemia, on the other hand, effects around 800 patients in England and is more common among those of Asian and Southern Mediterranean heritage.

With the main treatment for these conditions being blood transfusions from donors and most available blood being from those of European origin, nearly a fifth (17%) of patients experience negative side effects because of inaccurately matched blood. These side effects can lead to a patient’s condition getting worse and, in particularly bad cases, death.

Blood transfusion

NHS England chief executive, Amanda Pritchard, paid tribute to the health service’s ability to embrace innovation, heralding this world-first as just the latest example.

“This fantastic new programme will significantly transform care for people living with sickle cell disorder and thalassaemia – by using blood group genotyping, harmful side effects of transfusions will be reduced, hugely boosting patients’ quality of life.”

The health service has outlined that a similar programme for donors is also in the works, with £1m being given to NHS Blood and Transplant to initialise blood group genotyping in its molecular diagnostics laboratory.

Health minister, Neil O’Brien, similarly hailed the investment as a “potential game-changer” for those with sickle cell disease and thalassaemia.

“Matching blood more accurately is vital for sickle-cell and thalassaemia patients – we urgently need more blood donors from these communities to come forward as they are more likely to have the necessary blood type vital to treat these disorders.”

NHE September/October 2023

NHE September/October 2023

Empowering the next generation to lead the way in hard-to-treat cancers.

The September/October 2023 edition of NHE brings you expert comment and analysis on a range of key health sector topics, from digital transformation to navigating post-pandemic challenges.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

National Health Executive Podcast

Ep. 36
How interoperability can support the NHS's core goals
with Ed Platt

In episode 36 of the National Health Executive podcast, we were joined by Omnicell’s UK professional services director, Ed Platt, to discuss interoperability in the NHS, practical examples of where it can be leveraged best, the importance of the health service's digital transformation journey and more.

More articles...

View all